InsiderTrades.com logo

SPRC Insider Trading

Insider Ownership Percentage: 1.52%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $4,620.00

SciSparc Insider Trading History Chart

This chart shows the insider buying and selling history at SciSparc by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

SciSparc Share Price & Price History

Current Price: $9.45
Price Change: ▲ Price Increase of +0.72 (8.25%)
As of 06/3/2026 10:35 AM ET

This chart shows the closing price history over time for SPRC up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

SciSparc Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/1/2026Itschak ShremDirectorSell462$10.00$4,620.0010,596View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for SciSparc (NASDAQ:SPRC)

25.06% of SciSparc stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

SciSparc Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/9/2024Renaissance Technologies LLC39,700$32K0.0%N/A5.592%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
SciSparc logo
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
Read More on SciSparc

Today's Range

Now: $9.45
Low: $8.40
High: $10.28

50 Day Range

MA: $5.22
Low: $3.06
High: $10.59

52 Week Range

Now: $9.45
Low: $2.98
High: $80.10

Volume

63,797 shs

Average Volume

651,238 shs

Market Capitalization

$5.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.74

Who are the company insiders with the largest holdings of SciSparc?

SciSparc's top insider investors include:
  1. Itschak Shrem (Director)
Learn More about top insider investors at SciSparc.